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ABSTRACT
Novel anabolic drug targets are needed to treat osteoporosis. Having established a large national cohort with unexplained high bone
mass (HBM), we aimed to identify a novel monogenic cause of HBM and provide insight into a regulatory pathway potentially amenable
to therapeutic intervention. We investigated a pedigree with unexplained HBM in whom previous sequencing had excluded known
causes of monogenic HBM. Whole exome sequencing identified a rare (minor allele frequency 0.0023), highly evolutionarily conserved
missense mutation in SMAD9 (c.65T>C, p.Leu22Pro) segregating with HBM in this autosomal dominant family. The same mutation was
identified in another two unrelated individuals both with HBM. In silico protein modeling predicts the mutation severely disrupts the
MH1 DNA-binding domain of SMAD9. Affected individuals have bonemineral density (BMD) Z-scores +3 to +5, mandible enlargement,
a broad frame, torus palatinus/mandibularis, pes planus, increased shoe size, and a tendency to sink when swimming. Peripheral quan-
titative computed tomography (pQCT) measurement demonstrates increased trabecular volumetric BMD and increased cortical thick-
ness conferring greater predicted bone strength; bone turnover markers are low/normal. Notably, fractures and nerve compression
are not found. Both genome-wide and gene-based association testing involving estimated BMDmeasured at the heel in 362,924 white
British subjects from theUKBiobank Study showed strong associationswith SMAD9 (PGWAS = 6 × 10
−16; PGENE = 8 × 10
−17). Furthermore,
we found Smad9 to be highly expressed in bothmurine cortical bone–derived osteocytes and skeletal elements of zebrafish larvae. Our
findings support SMAD9 as anovelHBMgeneandapotential novel osteoanabolic target for osteoporosis therapeutics. SMAD9 is thought
to inhibit bone morphogenetic protein (BMP)-dependent target gene transcription to reduce osteoblast activity. Thus, we hypothesize
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SMAD9 c.65T>C is a loss-of-function mutation reducing BMP inhibition. Lowering SMAD9 as a potential novel anabolic mechanism for
osteoporosis therapeutics warrants further investigation. © 2019 The Authors. Journal of Bone and Mineral Research published by Amer-
ican Society for Bone and Mineral Research.
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Introduction
Age-related bone loss with deterioration of skeletal architec-ture leads to osteoporosis, affecting 8.2 million women and
2.0millionmenaged50 years andolder in theUnited States (US).(1)
Worldwide, osteoporosis causes more than 8.9 million fractures
annually.(1) Osteoporotic fractures and their treatment are a major
cause ofmorbidity andmortality, with annual US health care costs
exceeding $20 billion.(2) Most osteoporosis treatment approaches,
includingall oralmedications, reducebone resorptionandprevent
further bone loss, rather than enhance bone formation. Affordable
anabolic treatments, which can restore bone mass and skeletal
architecture, are much needed.
Romosozumab, a monoclonal antibody against sclerostin,
represents a new class of anti-osteoporosis drug, recently
approved by the FDA.(3,4) Sclerostin, a key inhibitor of bone for-
mation, was discovered through study of two rare syndromes
of extreme high bone mass (HBM) due to mutations in SOST.(5,6)
SOST encodes Sclerostin, which binds to low-density lipoprotein
receptor-related proteins 5 and 6 (LRP5 and LRP6) to prevent
activation of canonical WNT signaling in bone, resulting in
decreased bone formation. Gain-of-function mutations in LRP5
and LRP6 can also cause extreme HBM.(7,8) Together these scle-
rosing bone dysplasias are characterized by mandible enlarge-
ment with tori of the palate and mandible, bone overgrowth
leading to nerve compression, a tendency to sink when swim-
ming, and, importantly, resistance to fracture.(5,7,9) These impor-
tant gene discoveries validate the study of rare monogenic HBM
as an approach to identify novel therapeutic targets for drug
development toward osteoporosis treatments.
We have previously shown that HBM (defined as a total hip
and/or first lumbar vertebral bonemineral density [BMD] Z-score
of ≥ +3.2) is observed in 0.18% of dual-energy X-ray absorptiom-
etry (DXA) scans in the UK.(10) Most cases are unexplained; ie,
they do not carry mutations in established HBM genes.(9)
Although such HBM populations do show enrichment for com-
mon variant associations with established BMD-associated
loci,(11) we hypothesized that novel causes of monogenic HBM
remain to be determined. Thus, we aimed to identify novel
monogenic causes of HBM to provide insight into regulatory
pathways amenable to therapeutic intervention.
Materials and Methods
The UK HBM cohort
The HBM study is a UK-based multicenter observational study of
adultswith unexplainedHBM, identified incidentally on routine clin-
icalDXA scanning. Full details ofDXAdatabase screeningandpartic-
ipant recruitmenthavebeen reported(10) (SupplementalMethods in
FileS1). Inbrief,DXAdatabases containing335,115DXAscans across
13 UK centers were searched; all scans explained by artefact or
known causes of high BMD were excluded. Unexplained HBM was
defined as 1) first lumbar vertebra (L1) Z-score of ≥ +3.2 plus total
hip (TH)Z-score of≥+1.2 and/or 2) THZ-score ≥ +3.2 plus L1Z-score
of≥+1.2. A total of 533 unexplained HBM cases were invited to par-
ticipate; 248 (47%) were recruited. They passed on study invitations
to first-degree relatives and spouse/partner(s). Finally, 236 of
893 (26.4%) invited relatives were recruited, as were 61 of
217 (28.1%) invited spouses/partners.(10) All participants underwent
structured clinical assessment and DXA scanning (Supplemental
Methods in File S1). Peripheral quantitative computed tomography
(pQCT) scanswere performed at the distal andmid-shaft of the tibia
(4% and 66% from distal endplate) in the nondominant lower limb
using a Stratec XCT2000L (Stratec Medizintechnik, Pforzheim,
Germany) as published previously(12) (Supplemental Methods in
File S1). Two non-fasted EDTA samples were collected and serum
separated and frozen within 4 hours to −80C. Bone formation
(Procollagen type 1 amino-terminal propeptide [P1NP], total osteo-
calcin) and resorption (β-C-telopeptides of type I collagen [βCTX])
markers and sclerostin were measured (Supplemental Methods in
File S1). DNA was extracted from peripheral venous blood using
standard phenol/ chloroform extraction. Sanger sequencing of all
HBM index cases for exons 2, 3, and 4 of LRP5, SOST (including the
van Buchemdisease deletion), and LRP4 (exons 25 and26) excluded
seven individuals with LRP5 mutations and one with a SOST muta-
tion, leaving 240 unexplained HBM individuals.(9)
Anglo-Australasian Osteoporosis Genetics Consortium
(AOGC) HBM and LBM cases
The original AOGC extreme truncate population included 1128
Australian, 74 New Zealand, and 753 British women, aged 55 to
85 years, ≥5 years postmenopausal, with either HBM (age- and
sex-adjusted TH BMD Z-scores +1.5 to +4.0, n = 1055) or low bone
mass (LBM) (Z-scores −4.0 to −1.5, n = 900).(13) LBM cases were
excluded if they had secondary causes of osteoporosis
(as previously described(13)). Unrelated samples of white ancestry
with complete height and weight data and enough high-quality
genomic DNA were available in 947 individuals (426 AOGC high
and521AOGC lowBMD), fromwhich (computation capacity limited
sample size) the most extreme HBM cases were selected using a
threshold TH or LS Z-score ≥ +2.5, and themost extreme LBM cases
using a LS Z-score ≤ −0.5, so 126 HBM and 493 LBM samples were
chosen to undergo whole exome sequencing (WES).
Whole exome sequencing
Sequencing libraries for 859 samples (240 UK HBM, 126 AOGC
HBM, and 493 AOGC LBM) were constructed. Base calling,
sequence alignment and variant calling were performed as pre-
viously described(14) (details in Supplemental Methods in File S1).
Filtering pipeline applied to unexplained HBM pedigrees
After quality-filtering, data were analyzed for carriage of at least
one rare (either novel or maximum population-based minor
allele frequency [MAF] <0.005) nonsynonymous single-
nucleotide variant (SNV) or indel in a highly conserved region
(GERP score < 1.5) of a gene, carried by the affected individuals
and not carried by unaffected individuals (ie, autosomal
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dominant carriage model). Data were then filtered based on
functional prediction of SNVs using Polyphen(15) to identify
“probably damaging” and SIFT(16) “deleterious” SNVs. Compound
heterozygous and homozygous inheritance were also assessed.
Sanger sequencing validation of pedigree-based HBM
mutation
Polymerase chain reaction (PCR) amplification of identified
exons was performed on 50 ng genomic DNA (see Supplemental
Methods 4 in File S1). Electropherograms were aligned and ana-
lysed using sequence analysis software Genalys (Version 2.0 ß,
Masazumi Takahashi).
Multi-marker analysis of GenoMic annotation (MAGMA) in
UK Biobank
Gene-based tests of association were performed on 362,924
unrelated white British subjects (54% female) from the UK Bio-
bank study with ultrasound-derived heel estimated BMD (eBMD)
and high-quality genomewide HRC and 1000G/UK10K imputed
data (Supplemental Methods in File S1). Detailed methodology
has been published.(17) Gene-based tests of association were
implemented in MAGMA v1.06(18) using a multimodel approach
combining association results from three separate gene analysis
models: principal components regression, single-nucleotide
polymorphism (SNP)-wise mean chi-square model (ie, test sta-
tistic derived as sum of -log(SNP p value)) and SNP-wise top
chi-square model (test statistic derived as sum of -log(SNP
p value) for top SNPs) to produce an aggregate p value corre-
sponding to the association between each of the 19,361 pro-
tein coding genes (20 kb) and BMD, adjusting for age, sex,
genotyping array, assessment center, and 20 ancestry informa-
tive principal components, with gene-based significance
threshold (p < 2.87 × 10−6).(17)
Phenomewide association study (PheWAS)
PheWAS was conducted using GWASATLAS (https://atlas.ctglab.
nl/), an online database of publicly available summary results sta-
tistics from 4,155 GWAS from 295 unique studies across 2960
unique traits and 27 domains.(19) Significance for pleiotropic
associations used a traditional genome-wide significance thresh-
old for SNP-trait PheWAS (p < 5 × 10−8).(17)
Gene expression in murine osteocytes
Whole transcriptome sequencing data from the primary osteo-
cytes of four different bone types (tibia, femur, humerus, and cal-
varia) from mice (marrow removed, n = 8 per bone) were
analyzed. A threshold of expression was determined based on
the distribution of normalized gene expression for each sam-
ple.(20) “Expressed” genes were those exceeding this threshold
for all 8 of 8 replicates in any bone type. Osteocyte-enriched
expression of these genes in the skeleton was determined by
comparing transcriptome-sequencing data from bone samples
with osteocytes isolated versus those samples with marrow left
intact (n = 5 per group).(21)
Replication in high BMD populations
WES data from AOGC were analyzed to identify any individual
who carried the same rare (MAF < 0.025) mutation as identified
from analysis of the HBM pedigree. Polyphen(15) and SIFT,(16)
PMut(22) and MutationTaster(23) were used for in silico functional
prediction. When the same point mutation was identified in
more than one individual, haplotypes were compared between
index case samples genotyped using an Infinium OmniExpress-
12v1.0 GWAS chip read using an Illumina iScan (San Diego, CA,
USA), with genotype clustering performed using Illumina Bead-
Studio software.
Protein structural modeling
The amino-acid sequence of human SMAD9 was passed to the
HHPred server.(24) This located the best template structures in
the Protein Databank for theMH1 domain, 5×6G (mouse SMAD5;
92% identity), and the MH2 domain, 3GMJ (Drosophila melano-
gaster MAD; 75% identity). Modeler was used to build the
domain models according to the HHPred alignments.(25) Chi-
mera was used to introduce point mutations and remodel the
domain swapping in the SMAD9-MH1 model.(26)
Zebrafish studies
BMPre:GFP (Tg(5xBMPRE-Xla.Id3:GFP))(27) and sp7:GFP (Tg(Ola.sp7:
NLS-GFP))(28) transgenic fish (in London AB background) were
housed and maintained in standard conditions.(29,30) Experi-
ments were approved by the University of Bristol Animal Welfare
and Ethical Review Body (AWERB) and performed in accordance
with a UK Home Office project license. Developmentally staged
larvae (after euthanization in MS222) were fixed in 4% parafor-
maldehyde (1 hour), dehydrated to 100% methanol, and stored
at −20C before staining. Immunolabeling was as previously
described.(31) Primary antibodies were anti-Smad9 (rabbit poly-
clonal, Abcam, Cambridge, MA, USA, ab96698) used at a 1/100
dilution and anti-GFP (chicken polyclonal, Abcam, ab13970) used
at a 1/200 dilution in blocking buffer (5% horse serum). Second-
ary antibodies were used (A21206 and A11041, Invitrogen, Carls-
bad, CA, USA) in a 1/400 dilution and samples incubated with
DAPI (Sigma-Aldrich, St. Louis, MO, USA, 1/1000 dilution) to visu-
alize nuclei. Samples were mounted in 1% low melting point
agarose and imaged with a confocal laser scanning microscope
(Leica, Buffalo Grove, IL, USA, SP5II AOBS attached to a Leica
DM I6000 inverted epifluorescence microscope) using a 40× PL
APO CS (1.3 numerical aperture) lens. Images were processed
and color balanced in Fiji.(32)
Results
HBM pedigree with a segregating SMAD9 c.65T>C p.
Leu22Pro variant
We investigated a pedigree with unexplained and apparently
autosomal dominant HBM (Fig. 1),(9) identified from our large
UK HBM cohort(10) (Fig. S2).
Clinical phenotype
Clinical phenotypes of the UK family individuals are shown in
Table 1; extended clinical histories are provided in Supplemental
Results. In summary, affected individuals had high BMD Z-scores
and very high body mass index (BMI) and had not had any adult
fractures, nerve compression, or dental problems; however,
bone pain was common, without a clear cause. There was no
clinical history of intellectual impairment, pulmonary hyperten-
sion, vascular hypertension, hematological abnormalities,
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pubertal delay, or other clinical conditions. None had been
exposed to anabolic or antiresorptive medications.
III.1: Index case (c.65T>C, p.Leu22Pro)
The 33-year-old index case, with BMD Z-scores +3.2 at the total
hip and +4.5 at first lumbar vertebra (L1), had only sustained
one traumatic fracture at age 20 months. She reported lower
leg and ankle pain. She was tall (>97th centile) and obese, with
increased shoe size, a broad frame, enlarged mandible, and a
4 mm torus mandibularis. She had normal joints. Radiographs
showed increased cortical thickness and new bone formation
at the anterior inferior iliac spines bilaterally (Supplemental
Fig. S1 in File S1).
II.2: Mother of the index case (c.65T>C, p.Leu22Pro)
The 55-year-old affected mother, with BMD Z-scores +3.3 at the
total hip and at L1, had never sustained a fracture. Six years ear-
lier she had had a right calcaneal spur surgically removed. She
had widespread pain with a diagnosis of fibromyalgia. She was
tall (97th centile) and obese, with above average shoe size, a
broad frame, enlargedmandible, but no tori. She had a full range
of movement in all joints, bilateral knee crepitus, and bilateral
pes planus.
III.2: Half-sister to index case (c.65T>C, p.Leu22Pro)
The 22-year-old affected half-sister, with BMD Z-scores +4.8 at
the total hip and +2.6 at L1, had not fractured. She had had sciat-
ica for 5 years, lumbar back pain and fronto-temporal headaches
for 11 years, with a diagnosis of migraine. She was tall (93rd cen-
tile) and obese, with above average shoe size, a broad frame,
enlarged mandible, a torus palatinus in the midline of her hard
palate (3 cm × 7 mm), and normal joint movement.
I.2: Grandmother of index case (wild type)
The 75-year-old grandmother, who did not have HBM, had also
never sustained a fracture. She had widespread osteoarthritis
and on examination had reduced extension of the right elbow
and left knee, and bilateral knee crepitus. However, in contrast
to other family members, she was less overweight with normal
shoe size, frame, mandible, and no tori.
Fig. 1. The HBM pedigree and electrophoretogram images of a segregating SMAD9 c.65T>C, p.Leu22Pro variant.
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Sequencing of pedigree
WES identified a heterozygous missense variant in SMAD9
(SMAD family Member 9 referring to homologies to the Caenor-
habditis elegans SMA (small worm phenotype) and Drosophila
MAD (“Mothers Against Decapentaplegic”)) (NM 001127217:
exon2: c.65T>C, p.Leu22Pro), segregating with HBM (ie, present
in all three individuals with HBM (III.1, II.2, III.2) but absent from
I.2 (Fig. S2). This variant (rs111748421) is rare (Exome Aggrega-
tion Consortium [ExAC] minor allele frequency [MAF] 0.0023 in
European non-Finnish populations), affects a highly evolution-
arily conserved base (genomic evolutionary rate profiling [GERP]
5.53), and is predicted to be pathogenic by multiple protein-
prediction algorithms (deleterious by SIFT,(16) probably damag-
ing by Polyphen,(15) and disease causing by MutationTaster(23)
and PMut(22)).
A novel variant in CHRNA1 (cholinergic receptor, nicotinic,
alpha 1) (c.560T>C, p.Leu187Pro) was also identified (GERP
5.29). Mutations in CHRNA1 have been associated with congeni-
tal myasthenic syndromes (OMIM#100690), not present in this
pedigree. No variants were identified when applying a com-
pound heterozygous or an autosomal recessive inheritance
model.
Sequencing of other HBM cases identifies two further
isolated HBM cases harboring a c.65T>C, p.Leu22Pro
variant
WES of a further 366 HBM cases (240 isolated cases from the UK
cohort with a total hip (TH) or L1 Z-score ≥+3.2 and 126 individ-
uals from the Anglo-Australasian Osteoporosis Genetics Consor-
tium (AOGC)(33) with either a total hip and/or lumbar spine
(LS) Z-score between +2.5 and +4.0) (Supplemental Fig. S2 in File
S1) identified two individuals with the same SMAD9 c.65T>C, p.
Leu22Pro variant. Haplotypic analysis confirmed these women
were neither related to each other nor to the pedigree described
above.
Clinical phenotype
Isolated HBM case (c.65T>C, p.Leu22Pro) from the UK (Table 1;
Supplemental Fig. S3 and Results in File S1). This 55-year-old
female, with BMD Z-scores +5.0 at the total hip and +4.7 at L1,
had never fractured and had no symptoms of nerve compres-
sion. Her adult left upper cuspid tooth had never erupted; wis-
dom teeth had been extracted for overcrowding. She had
noticed her own mandible enlargement. She had a congenital
astigmatism of her left eye with poor vision and congenital bilat-
eral pes planus. Height was normal (30th centile). She was obese
with a broad frame, mandible enlargement, but no tori. She had
normal joints.
Isolated HBM case (c.65T>C, p.Leu22Pro) from Australia
This 57-year-old female, with BMD Z-scores +3.0. at the total hip
and +2.7 at L1, reported a nose fracture as a child. Height was on
the 45th centile and she was overweight. She did not have any
history of conditions affecting bone health and had not received
antiresorptive or anabolic medications. No further clinical details
were available.
Tibial pQCT evaluation
All members of the HBM pedigree, plus the additional isolated
HBM case from the UK underwent pQCT scanning of the tibia
(Table 2; Supplemental Table S1 and Supplemental Fig. S4 in File
S1). To set these findings in context, the mean (SD) values from
the four c.65T>C, p.Leu22Pro SMAD9 HBM cases were compared
against values from 76 unrelated female HBM cases (without
SMAD9, LRP5, LRP4, or SOSTmutations) and 32 female family con-
trols with normal DXA-measured BMD who had had pQCT scans
Table 2. Distal and Mid-Shaft Tibial pQCT Measures in High Bone Mass (HBM) Cases Compared With Female HBM Cases Without SMAD9,
LRP5, LRP4, SOST Mutations, and Female Family Controls With Normal BMD
SMAD9 HBM cases
Leu22Pro n = 4
Mean (SD)
WT female HBM
cases1 n = 76
Mean (SD) p Value2
Female family
controls with
normal BMD n = 32
Mean (SD) p Value3
Age (years) 41.3 (16.5) 60.8 (12.3) 54.8 (13.5)
Total hip BMD Z-score +3.8 +2.9 +0.39
4% distal tibia Total bone area (mm2) 1038 (160.6) 1052 (122.6) 0.820 817.1 (223.5) 0.066
Trabecular BMD (mg/cm3) 342.3 (13.3) 324.3 (22.5) 0.118 308.0 (24.6) 0.010
Cortical thickness (mm) 2.12 (0.79) 1.04 (0.81) 0.011 0.87 (0.83) 0.007
66% mid-shaft
tibia4
Total bone area (mm2) 608.3 (4.7) 601.5 (81.9) 0.886 572.7 (73.9) 0.416
Cortical BMD (mg/cm3) 1150 (10.1) 1126 (35.9) 0.255 1111 (65.7) 0.319
Cortical thickness (mm) 4.96 (0.13) 4.37 (0.62) 0.104 3.80 (0.71) 0.008
Cortical bone area (mm2) 356.3 (9.1) 316.6 (36.6) 0.065 274.1 (42.4) 0.002
Cortical/total bone area (%) 58.6 (1.1) 53.3 (7.57) 0.236 48.3 (8.34) 0.043
SSI (mm3) 1680 (21.1) 1506 (236.6) 0.211 1298 (248.2) 0.013
Muscle area (mm2) 8334 (536.5) 6939 (980.8) 0.017 6542 (1033) 0.006
Muscle density (mg/cm3) 42.1 (1.5) 40.1 (4.0) 0.392 40.2 (3.1) 0.323
BMD = bone mineral density; SD = standard deviation; SSI = strength strain index; WT = wild type.
1 Female subgroup (without SMAD9, LRP5, LRP4, SOSTmutations) analyzed using data previously published, collected, and analyzed with the same pro-
tocols as SMAD9 HBM cases.(9)
2 Analysis of SMAD9 HBM cases versus WT HBM cases.
3 Family controls with normal BMD.
4 n = 3.
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following the same protocol.(12) The four SMAD9 HBM cases had
greater trabecular density, cortical area and thickness, and pre-
dicted bone strength (strength stain index [SSI]) than other
HBM cases and, to a greater extent, than unaffected family con-
trols. Muscle size (cross-sectional area) was also notably larger
in the SMAD9 HBM group (Table 2).
Sequencing of low bone mass (LBM) cases
WES data from 473 women with LBM from the AOGC consortium
with TH Z-scores between −1.5 and −4.0 and a LS Z-score ≤−0.5,
obtained using similar methodology to the AOGC HBM cases,
was interrogated (Supplemental Fig. S2 in File S1). The c.65T>C,
p.Leu22Pro SMAD9 variant was not observed.
Common SMAD9-associated genetic variants and BMD
Publicly available data from a recent population-based genome-
wide association study (GWAS) of eBMD (estimated BMD by heel
ultrasound in the UK Biobank study)(17) were used to investigate
variants surroundingboth SMAD9 andCHRNA1. Regional association
plots suggested that SNPs intersecting SMAD9 are strongly associ-
ated with eBMD (lead SNP rs12427846 [MAF 0.25], β 0.02, SE 0.002,
p = 5.5 × 10−16; Fig. 2). In contrast, SNPs surrounding CHRNA1 were
not robustly associated with eBMD (Supplemental Fig. S5 in File S1).
These observations were further supported by gene-based tests of
association performed in-house using 362,924 unrelated white Brit-
ish subjects from the UK Biobank Study. Specifically, SMAD9 was
more strongly associated with eBMD (PJOINT = 7.94 × 10
−17), when
compared with neighboring genes within800 kb (p > 2.4 × 10−2)
(Supplemental Table S2 in File S1). No such enrichment was found
for CHRNA1 (Supplemental Table S3 in File S1). Further investigation
of rs12427846 in the UK Biobank Study identified weak associations
with body weight (β −0.14, SE 0.04, p = 1.6 × 10−3) and with
height (β −0.07, SE 0.03, p = 3.5 × 10−3) with effects in the
opposite direction from that found with eBMD; however,
adjustment for weight and height did not attenuate the strong
association between rs12427846 and eBMD reported above.
Interrogating the GWAS Catalog (https://www.ebi.ac.uk/gwas/)
did not identify associations of the rare (MAF 0.0014) variant
rs111748421 with any trait (neither bone-related nor any
other).
Fig. 2. GWAS for eBMDmeasured in UK Biobank: Regional association plot for the locus containing SMAD9. Top panel: circles show unconditioned GWAS
p values and genomic locations of imputed SNPs within 800 kb of the 50 and 30 UTR of each gene. Colors indicate varying degrees of pairwise linkage
disequilibrium between the lead eBMD-associated SNP (rs12427846, purple diamond) and all other SNPs. Second panel: Vertical shaded areas correspond
to locations of DNase I hypersensitive sites (DHSs) characteristic of skeletalmusclemyoblasts cell line (E120), osteoblast primary cells (E129), mesenchymal
stem cell–derived chondrocyte cultured cells (E049) and mesenchymal stem cell–derived adipocyte cultured cells (E023). Red shading depicts intersec-
tions between DHSs and genomewide significant SNPs. Black shading denotes instances in which any other SNPs intersect DHSs. Third panel: Blue circle
shows the position of the putative causal variant c.65T>C, p.Leu22Pro. Fourth panel: Horizontal lines represent genes with vertical lines annotating loca-
tion of exons. Arrows indicate the direction in which each gene is transcribed.
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Fig. 3. Legend on next page.
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Phenomewide association study
PheWAS involving nearly 3000 traits(19) identified no clear evi-
dence for pleiotropy for the c.65T>C, p.Leu22Pro SMAD9 variant
(rs111748421) (Supplemental Fig. S6 and Supplemental Table S4
in File S1). Analysis involving the common SMAD9 variant
(rs12427846) revealed robust pleiotropic associations with BMD
traits. Similarly, a gene-based PheWAS of SMAD9 identified
robust evidence of gene-level pleiotropy with BMD. To investi-
gate further possible pleiotropic associations with metabolic
phenotypes, we looked up rs111748421 and rs12427846 in the
Myocardial Infarction Genetics and CARDIoGRAM Exome meta-
analysis(34,35) and the subsequent meta-analysis to which results
from UK Biobank SOFT CAD GWAS and CARDIoGRAMplusC4D
1000 Genomes-based GWAS were added.(36) No association
was found for rs111748421 in either. Although rs12427846 was
not present in the first meta-analysis, the eBMD-increasing allele
was only nominally associated with the composite cardiovascu-
lar disease outcome in the second (log OR 0.03 [SE 0.01],
p = 9 × 10−4; significance threshold p < 5 × 10−8).(36)
Smad9 expression in murine osteocytes
We next determined whether Smad9 and Chrna1 are expressed
in osteocytes, the master cell regulators in the skeleton and key
regulators of bone mass,(37) and enriched in osteocytes com-
pared with other cells in bone.(21) Smad9 mRNA was highly
expressed in murine osteocytes, whereas Chrna1 was not
(Supplemental Table S5 in File S1).
Smad9 expression in zebrafish skeletal tissue
We also examined Smad9 protein expression in the developing
zebrafish skeleton(38) at 6 and 7 days post fertilization (dpf)
(Fig. 3A). A focus of Smad9 expression was observed at the dor-
sal tip of the opercle, an intramembranous bone overlying the
gills, adjacent to but distinct from a region of bone morphoge-
netic protein (BMP) reporter activity (Fig. 3B). The opercula mus-
cle group also showed evidence of BMP reporter activity,
whereas Smad9 expression at this site was absent.
Smad9-expressing cells in the opercle were negative for the
osteoblast marker, sp7 (osterix), suggesting they are likely to
represent pre-osteoblasts (Fig. 4C and Supplemental Movie S1
in File S1). Equivalent findings were observed in the
branchiostegal ray bones and in the notochord at 6 and 7 dpf
(Supplemental Fig. S7 in File S1).
SMAD9 protein structural modeling
SMAD9 is a TGF-beta family member DNA binding transcription
factor. Phosphorylation by BMP-ligand-bound type 1 receptor
kinase activates SMAD9, which translocates from the cyto-
plasm to the nucleus to regulate target gene expression.(39)
The seven exons of human SMAD9 encode a protein of
467 amino acids that contains two MAD-homology
(MH) domains (MAD: Mother against Dpp) separated by a linker
region (Fig. 4). The p.Leu22Pro SMAD9 mutation is located
within the MH1 domain responsible for DNA binding (Fig. 4)
and lies in the hydrophobic face of the N-terminal alpha helix
(helix-1) (Fig. 5, Supplemental Movie S2 in File S1). Helix-1 packs
against a groove made by helix-2 and -3 within MH1, forming
part of the hydrophobic core of this domain. Substitution of
leucine by proline will: 1) introduce a less hydrophobic residue
into this position; and 2) compromise the α-helical fold by dis-
rupting the canonical hydrogen bonding of helix-1. Thus,
modeling suggests that this mutation will disrupt the MH1
domain so severely that SMAD9 can no longer bind DNA and/or
will be unstable, leading to protein degradation.
Discussion
We report the first HBM pedigree with a segregating SMAD9
mutation, with replication in two further unrelated individuals
with HBM. SMAD9 (also known as SMAD8, MADH6, and MADH9)
encodes a downstream modulator of the BMP signaling path-
way. BMPs, members of the TGF-β superfamily, induce the forma-
tion of bone and cartilage.(40) SMADs, activated by ligand-
binding of cell surface BMP receptors, mediate downstream
intracellular signaling and biological responses induced by
BMPs.(41) Smad6 and Smad7 both inhibit BMP receptor activa-
tion and downstream signaling, as does Smad9 by more direct
transcriptional repression.(39) Our in silico protein modeling pre-
dicts that the p.Leu22Pro mutation severely disrupts the struc-
ture of the MH1 DNA binding domain of SMAD9, leading to loss
of function.
Few previous studies have examined sites of Smad9 tissue
expression. We have confirmed that Smad9 is expressed in
mouse cortical bone-derived osteocytes and the Smad9 protein
FIG. 3. Smad9 protein expression in the larval zebrafish opercle bone. (A) Schematic of the larval zebrafish head (6 days post fertilization [dpf], lateral
view), showing visible ossified elements (red) and the main muscle groups (green) that are green fluorescent protein (GFP)-positive under control of
the BMP-responsive elements promoter (BMPre) transgenic reporter line (BMPre:GFP). The black box indicates the location of the intramembranous oper-
cle bone as shown in B and C. (B) Distinct tissue distribution of Smad9- and BMP-expressing cells (7 dpf). Upper left panel: BMPre:GFP-positive cells (white)
in the levator operculi muscle group (white arrow) and ventral (V) side of the opercle (OP; dotted blue outline); upper middle: distinct group of
Smad9-positive cells (white) in the dorsal (D) tip of the opercle; upper right: merged view showing distinct tissue expression of BMPre:GFP-positive cells
(green) and Smad9-positive cells (purple); lower left: gray box inset (i) showing faint cap of BMPre:GFP-positive cells at the dorsal tip of the opercle (red
arrow); lower middle: cluster of Smad9-positive cells; lower right: merged view confirming non-overlapping distribution of BMPre:GFP-positive cells and
Smad9-positive cells. Images from n = 4 larvae. (C) Distinct tissue distribution of Smad9- and osterix (Sp7)-expressing cells (6 dpf). Upper left: Sp7:GFP-
positive osteoblasts (OB; white) within the opercle; upper middle: Smad9-positive cells (white) in the antero (A)-dorsal tip of the opercle (red arrow); upper
right: merged view showing separation of Sp7:GFP-positive cells (green) and Smad9-positive cells (purple) (Supplemental Movie S1 in File S1); lower left:
the inset (i, gray box) shows few Sp7:GFP-positive osteoblasts within the dorsal tip of the opercle; lowermiddle: cluster of Smad9-positive cells; lower right:
merged view confirming non-overlapping distribution of Sp7:GFP- and Smad9-positive cells. Images from n = 6 larvae. (B, C) Scale bar = 20 μm; all are
maximum-intensity z-projection confocal images. A = anterior; BR = branchiostegal ray; CL = cleithrum; D = dorsal; M = muscle; MC = Meckel’s cartilage;
MX = maxilla; OB = osteoblast; OP = operculum; P = posterior; V = ventral.
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in skeletal elements of zebrafish larvae. Moreover, we observed
that BMP reporter activity in zebrafish was absent at sites of
Smad9 expression, consistent with a functional role in BMP
repression.(39) Mutant mouse models with a LacZ insertion caus-
ing Smad9 truncation have not undergone BMD phenotyping;
however, they have shown strong LacZ expression (under con-
trol of an endogenous Smad9 promoter) within developing skel-
etal sites (eg, ribs, maxilla, mandible), gut, and lungs.(42,43) Taken
together, our findings suggest that SMAD9 c.65T>C is a loss-of-
function mutation, causing HBM through a novel mechanism
of enhanced bone formation due to reduced BMP inhibition.
Further, we have shown that the region containing SMAD9 is
strongly associated with BMD within the general population.
Common variants intersecting SMAD9 associate with
population-based measures of eBMD, as evidenced recently by
fine-mapping of target genes(17,44) and from our gene-based
tests of association presented here. Furthermore, rs12427846
(the lead SNP from these eBMD results) is associated with DXA-
measured total body BMD(45) and fracture risk,(17) also consistent
with associations with BMD identified in our PheWAS. These find-
ings provide further evidence of the importance of SMAD9 in
bone biology and are equivalent to reported associations for
common variants annotated to LRP5 and SOST genes, both sim-
ilarly implicated in monogenic HBM disorders.(46,47)
We have previously estimated unexplained HBM to have a
prevalence of 0.181% amongst a DXA-scanned adult population
in the UK.(10) As two of 248 cases fulfilling our stringent HBM phe-
notype definition (Supplemental Fig. S2 in File S1) were found to
harbor the c.65T>C p.Leu22Pro SMAD9 variant (rs111748421), we
would estimate prevalence of SMAD9 HBM as approximately 1 in
100,000 (1.46 × 10−5), less common than LRP5 HBM.(9) As
rs111748421 has a reported MAF of 0.0028, this raises the possi-
bility of incomplete penetrance, variable expressivity, gene–
gene or gene–environment interaction with a currently
unknown factor; it is also possible that rs111748421 might be
in linkage disequilibrium (LD) with an intronic regulatory variant
not captured by WES.
The clinical phenotype of c.65T>C, p.Leu22Pro SMAD9 HBM
includes mandible enlargement, a broad frame, torus palatinus,
pes planus, increased shoe size, and, in 2 of 5 subjects, a ten-
dency to sink when swimming. Adult fractures were not
reported, raising the possibility of increased skeletal strength,
supported by evidence of greater cortical bone and an increased
strength-strain index (SSI) quantified by pQCT (discussed further
below), both of which promote fracture resistance. Mandible
enlargement, torus palatinus, a tendency to sink when swim-
ming, and an absence of adult fractures are reminiscent of
LRP5 HBM.(7,48) Encouragingly, unlike sclerosteosis (due to
Fig. 4. Position of c.65T>C p.Leu22Pro variant within SMAD9.
Fig. 5. (A) Wild-type (WT) SMAD9MH1 domain (light green ribbonwith helix-1 in light blue) binding the DNA helix (dark blue/dark green). L22 is shown in
blue space filling. (B) L22P, shown in red space filling, is predicted to severely disrupt the structure of the MH1 domain. Supplemental Movie S2 in File S1:
3-dimensional rotating image.
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anabolic SOST mutations) and some LRP5 HBM cases,(9,49) nerve
compression was not a feature of SMAD9 HBM.
The musculoskeletal phenotype of p.Leu22Pro SMAD9 HBM
includes high BMD Z-scores (+3 to +5), with increased fat and
lean mass. Although morbid obesity with increased stature was
found in 3 of 5 SMAD9 HBM cases, this was not ubiquitous to
all. The increases in BMD of +3.3 to 5 SDs above normal exceeded
increases in fat-mass index of +0.9 to 3.4, supporting HBM as the
primary phenotype, rather than high BMD occurring as a conse-
quence of high fat mass.(50) Furthermore, fat-associated pheno-
types were not identified in our PheWAS. pQCT revealed
increased volumetric trabecular bone density with greater corti-
cal thickness and area, suggesting reduced bone remodeling to
reduce endosteal expansion. In support, bone turnover markers
are at the lower end of the normal range. This phenotypemimics
that previously described for human LRP5 HBM(51) although
plasma sclerostin is not elevated, in contrast to LRP5 HBM,(52)
suggesting that a negative feedback loop downregulating WNT
signaling is not present. pQCT further identified larger muscle
size in SMAD9 HBM cases, including in the independent UK case
with normal stature. This contrasts with findings from our zebra-
fish studies that Smad9 expression is absent from skeletal muscle
tissue, as is also observed in murine models.(43) Given the well-
recognized cross-talk between muscle and bone(53) and the
large BMI of these individuals, it is conceivable that the increase
in muscle size is secondary to a need to carry the substantial
weight of both fat and bone mass. However, similar increases
in muscle size have not been reported in other monogenic
HBM conditions (ie, LRP5 or SOST HBM) with equivalent BMD.
A clinical report of 13q13.3-q21.3 deletion, leading to haploin-
sufficiency of SMAD9 amongst other genes, identified a pheno-
type of skeletal overgrowth with infant height >95th
percentile, consistent with the adult phenotype we describe,
implicating SMAD9 in the regulation of linear growth.(54) We
found limited, but consistent, evidence that SMAD9 HBM may
affect longitudinal growth. Although differences in height can
artefactually affect DXA-measured BMD, pQCT measures of
increased trabecular bone density and cortical thickness are usu-
ally more independent of body size. Heterozygous truncating
SMAD9mutations are associated with primary pulmonary hyper-
tension (OMIM#615342),(55) a phenotype not apparent in our
HBM cases. Reported mutations affect a different domain from
the mutation observed here, with p.Cys202X(55) and p.
Arg294X(56) truncating the SMAD9 protein in the linker region
between MH1 and MH2. A truncating mutation (p.Arg247X) has
been associated with cerebral arteriovenous malformations in
childhood.(57) An activating heterozygous p.Val90Met germline
mutation, affecting the 4th α-helix of MH1 and close to the
DNA binding interface, has been described in one pedigree with
hamartomatous polyposis.(58) In contrast to p.Leu22Pro, p.Val90-
Met appears to be a gain-of-function mutation, thought to arise
from a steric clash, prompting a His104 residue to enhance DNA
binding.(58) Such examples of diverse phenotypes arising from
mutations in differing exons of the same gene are well recog-
nized, eg, differing mutations in FBN1 (Fibrillin 1) can cause Mar-
fan syndrome (with associated tall stature) (OMIM#154700),
acromicric dysplasias (with short stature) (OMIM#102370), or stiff
skin syndrome (OMIM#184900).(59–61)
We are only aware of one other skeletal dysplasia reported
in association with an inhibitory SMAD (which include SMAD6
and SMAD7). A rare SMAD6 mutation has been associated
with susceptibility to nonsyndromic midline craniosynostosis
7 (OMIM#617439), but only in the context of co-inheritance of
a common variant in BMP2 strongly associated with this condi-
tion, a rare example of two locus inheritance.(62) Interestingly,
amongst the 1103 conditionally independent SNPs reaching
genomewide significance in the UK Biobank eBMD GWAS (pop-
ulation n = 426,824), as well as identifying the SMAD9 locus, four
novel SNPs annotating to SMAD7 were reported (plus three
established SNPs associated with SMAD3), all suggesting varia-
tion in inhibitory SMADs is likely of functional importance in
human bone biology.(17)
The phenotype we describe here contrasts with that of acti-
vating mutations of the BMP receptor, ACVR1, which increase
BMP signaling. However, in contrast to p.Leu22Pro SMAD9
HBM, ACVR1 mutations lead to a fatal condition, fibrous ossifi-
cans progressiva (FOP, OMIM#135100).(63) In FOP, muscle tissue
differentiates into bone after trivial injury, resulting in the forma-
tion of mature bone at multiple extraskeletal sites. ACVR1 muta-
tions may produce a more severe phenotype, compared with
loss-of-function mutations in SMAD9 reported here, since ACVR1
also activates non-SMAD-dependent BMP signaling cascades,
such as the NF-κB and p38 MAP kinase (p38MAPK) pathways,
which are upregulated in FOP ACVR1 R206H monocytes.(64)
Given the benign phenotype observed in c.65T>C, p.Leu22Pro
SMAD9 carriers, our findings suggest that SMAD9 is worth con-
sideration as a drug target for osteoporosis. Our zebrafish studies
suggest that Smad9 is expressed in pre-osteoblasts, consistent
with the profile of an anabolic target capable of stimulating
new bone formation through recruitment of early osteoblast
progenitors. Given the pathological consequence of excess
BMP activation in FOP, this pathway has not been prioritized as
a possible therapeutic target in osteoporosis, despite the pro-
found bone anabolic potential. Interestingly, phosphorylation
of Smad9, as part of the Smad1/5/9 heterotrimer, has been
researched in relation to fracture healing and bone regeneration:
G-protein-coupled receptor kinase 2-interacting protein-1 (GIT1),
a shuttle protein in osteoblasts, regulates Smad1/5/9 phosphor-
ylation, which in turn mediates BMP2 regulation of Runx2
expression and thus endochondral bone formation at fracture
sites.(65,66) Moreover, BMP has been administered locally to pro-
mote bone repair after surgery.(67) Based on our findings, it is
tempting to speculate that treatments suppressing SMAD9 activ-
ity might prove useful in treating osteoporosis, fractures, and
possibly also sarcopenia. The potential pleiotropic association
between one SMAD9 variant and a composite cardiovascular
phenotype represents the results of lifelong exposure to a vari-
ant rather than any potential short-term perturbations in a gene
pathway as might be exploited therapeutically.
Our study has limitations. All individuals with c.65T>C, p.
Leu22Pro SMAD9 HBM were female, reflecting the study design
that favored those with a historical DXA scan who are more likely
to be female. Whether findings will be similar inmen is unknown,
although no sex-gene interaction has been described for the
LRP4, LRP5, LRP6, or SOST sclerosing bone dysplasias. In the
recent UK Biobank eBMD GWAS, LD score regression analyses
suggested that the genetic architecture influencing male and
female eBMD was largely shared with some significant differ-
ences between the sexes (rG = 0.91, SE = 0.012, p < 0.001),(17)
consistent with earlier epidemiological studies.(68) The small
sample of SMAD9 HBM cases (n = 4 with pQCT) limited our ability
to robustly evaluate associations statistically. The c.65T>C, p.
Leu22Pro mutation is a reported SNP carried within the general
population (eg, in the UK, an estimated 92,428 people might
be expected to carry this mutation). This may be the case, given
there is no indication that the phenotype affects reproductive
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fitness and HBMwill not be overt unless a DXA scan is performed.
Our GWASwas based on estimated heel BMDquantified by ultra-
sound rather than DXA-measured BMD. Estimated heel BMD is
not used routinely in clinical practice. However, we have previ-
ously demonstrated a strong overlap between genetic loci iden-
tified by eBMD GWAS and by DXA-measured BMD GWAS.(44)
We report SMAD9 as a novel HBM-causing gene. The clinical
phenotype of c.65T>C, p.Leu22Pro SMAD9 HBM has many fea-
tures in common with that of LRP5 HBM but lacks the deleterious
features that characterize SOST HBM (sclerosteosis). As reported
for both LRP5 and SOST, we demonstrate that a rare mutation
in SMAD9 is associated with an extreme bone phenotype and
that common variation in SMAD9 affects bone density within
the general population. The role of SMAD9 in bone biology is
supported by our finding of high levels of Smad9 expression in
murine osteocytes and in skeletal elements of zebrafish larvae.
Smad9 is thought to inhibit BMP signaling to reduce osteoblast
activity; thus, we hypothesize SMAD9 c.65T>C is a loss-of-
function mutation reducing BMP inhibition, ultimately leading
to enhanced bone formation. Our findings support SMAD9,
and its role within the SMAD9-dependent BMP signaling path-
way, as a potential novel anabolic target for osteoporosis thera-
peutics that warrants further investigation.
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